Inflammatory role and prognostic value of platelet chemokines in acute coronary syndrome

Thrombosis and Haemostasis

Volumn 112, Issue 6, 2014, Pages 1277-1287

  Blanchet, Xavier ^a   Cesarek, Katja ^b   Brandt, Johanna ^c   Herwald, Heiko ^d   Teupser, Daniel ^c   Küchenhoff, Helmut ^c   Karshovska, Ela ^a   Mause, Sebastian F ^b   Siess, Wolfgang ^a   Wasmuth, Hermann ^e   Soehnlein, Oliver ^a,h   Koenen, Rory R ^a,f   Weber, Christian ^a,f   von Hundelshausen, Philipp ^a,g  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d LUND UNIVERSITY   (Sweden)

^e Medizinische Klinik   (Germany)

^f MAASTRICHT UNIVERSITY   (Netherlands)

^g DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^h UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Acute coronary syndrome; Atherosclerosis; Chemokines; Neutrophils; Platelets

Indexed keywords

ANTICOAGULANT AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; AUTACOID; BIOLOGICAL MARKER; CARRIER PROTEIN; CATIONIC ANTIMICROBIAL PROTEIN CAP 37, HUMAN; CCL5 PROTEIN, HUMAN; CHEMOKINE; HEPARIN; PEROXIDASE; PLASMA PROTEIN; RANTES;

ACUTE CORONARY SYNDROME; AGED; BLOOD; CASE CONTROL STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECTS; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; INFLAMMATION; MALE; METABOLISM; MIDDLE AGED; NEUTROPHIL; PREDICTIVE VALUE; PROGNOSIS; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL MODEL; THROMBOCYTE; THROMBOCYTE COUNT; TIME;

ACUTE CORONARY SYNDROME; AGED; ANTICOAGULANTS; ANTIMICROBIAL CATIONIC PEPTIDES; BIOLOGICAL MARKERS; BLOOD PLATELETS; BLOOD PROTEINS; CARRIER PROTEINS; CASE-CONTROL STUDIES; CHEMOKINE CCL5; CHEMOKINES; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPARIN; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LINEAR MODELS; MALE; MIDDLE AGED; NEUTROPHILS; PEROXIDASE; PLATELET COUNT; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 84914144249     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-02-0139     Document Type: Article

References (44)

1. Massberg S, et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 2002; 196: 887–896.
2. Huo Y, et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003; 9: 61–67.
3. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011; 17: 1410–1422.
4. Soehnlein O. Multiple roles for neutrophils in atherosclerosis. Circ Res 2012; 110: 875–888.
5. Montecucco F, et al. Systemic and intraplaque mediators of inflammation are increased in patients symptomatic for ischaemic stroke. Stroke 2010; 41: 1394–1404.
6. Montecucco F, et al. The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. Eur Heart J 2012; 33: 846–856.
7. Quercioli A, et al. Receptor activator of NF- kappaB ligand (RANKL) increases the release of neutrophil products associated with coronary vulnerability. Thromb Haemost 2012; 107: 124–139.
8. Dutta P, et al. Myocardial infarction accelerates atherosclerosis. Nature 2012; 487: 325–329.
9. Liehn EA, et al. Repair after myocardial infarction, between fantasy and reality: the role of chemokines. J Am Coll Cardiol 2011; 58: 2357–2362.
10. Karshovska E, et al. Platelet chemokines in health and disease. Thromb Haemost 2013; 110: 894–902.
11. Koenen RR, et al. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med 2009; 15: 97–103.
12. Gleissner CA, et al. CXCL4 downregulates the atheroprotective hemoglobin receptor CD163 in human macrophages. Circ Res 2010; 106: 203–211.
13. Struyf S, et al. Platelets release CXCL4L1, a nonallelic variant of the chemokine platelet factor-4/CXCL4 and potent inhibitor of angiogenesis. Circ Res 2004; 95: 855–857.
14. Struyf S, et al. Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3. Blood 2011; 117: 480–488.
15. Sarabi A, et al. CXCL4L1 inhibits angiogenesis and induces undirected endothelial cell migration without affecting endothelial cell proliferation and monocyte recruitment. J Thromb Haemost 2011; 9: 209–219.
16. De Sutter J, et al. PF-4var/CXCL4L1 predicts outcome in stable coronary artery disease patients with preserved left ventricular function. PLoS One 2012; 7: e31343.
17. Sachais BS, et al. Elimination of platelet factor 4 (PF4) from platelets reduces atherosclerosis in C57Bl/6 and apoE-/- mice. Thromb Haemost 2007; 98: 1108–1113.
18. Scirica BM, et al. Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial. Eur Heart J 2011; 32: 697–705.
19. Gautam N, et al. Heparin-binding protein (HBP/CAP37): a missing link in neutrophil-evoked alteration of vascular permeability. Nat Med 2001; 7: 1123–1127.
20. Soehnlein O, et al. Neutrophil secretion products pave the way for inflammatory monocytes. Blood 2008; 112: 1461–1471.
21. Berres ML, et al. Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. J Clin Invest 2010; 120: 4129–4140.
22. Burkhart JM, et al. The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways. Blood 2012; 120: e73–82.
23. Hartwig H, et al. Platelet-derived PF4 reduces neutrophil apoptosis following arterial occlusion. Thromb Haemost 2014; 111: 562-564.
24. Sabatine MS, et al. Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy- Thrombolysis in Myocardial Infarction 18 trial)substudy. J Am Coll Cardiol 2002; 40: 1761–1768.
25. Holmer-Jensen J, et al. Differential effects of dietary protein sources on postprandial low-grade inflammation after a single high fat meal in obese non-diabetic subjects. Nutrition J 2011; 10: 115.
26. Aye MM, et al. Acute Hypertriglyceridemia Induces Platelet Hyperactivity That is Not Attenuated by Insulin in Polycystic Ovary Syndrome. J Am Heart Assoc 2014; 3: e000706.
27. Soehnlein O, et al. Distinct functions of chemokine receptor axes in the atherogenic mobilisation and recruitment of classical monocytes. EMBO Mol Med 2013; 5: 471–481.
28. Morrow DA. Appraisal of myeloperoxidase for evaluation of patients with suspected acute coronary syndromes. J Am Coll Cardiol 2007; 49: 2001–2002.
29. Baldus S, et al. Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration. J Clin Invest 2001; 108: 1759–1770.
30. Rudolph TK, et al. Contribution of myeloperoxidase to smoking-dependent vascular inflammation. Proc Am Thoracic Soc 2008; 5: 820–823.
31. Mazor R, et al. Primed polymorphonuclear leukocytes constitute a possible link between inflammation and oxidative stress in hyperlipidemic patients. Atherosclerosis 2008; 197: 937–943.
32. Wanten GJA, et al. Saturated triglycerides and fatty acids activate neutrophils depending on carbon chain-length. Eur J Clin Invest 2002; 32: 285–289.
33. Ritter L, et al. Exaggerated Neutrophil-Mediated Reperfusion Injury after Ischaemic Stroke in a Rodent Model of Type 2 Diabetes. Microcirculation 2011; 18: 552–561.
34. Zhang S, et al. Heparin-induced Leukocytosis Requires 6-O-Sulfation and Is Caused by Blockade of Selectin- and CXCL12 Protein-mediated Leukocyte Trafficking in Mice. J Biol Chem 2012; 287: 5542–5553.
35. Kraaijeveld AO, et al. CC chemokine ligand-5 (CCL5/RANTES) and CC chemokine ligand-18 (CCL18/PARC) are specific markers of refractory unstable angina pectoris and are transiently raised during severe ischaemic symptoms. Circulation 2007; 116: 1931–1941.
36. Brummel-Ziedins K, et al. Thrombin generation in acute coronary syndrome and stable coronary artery disease: dependence on plasma factor composition. J Thromb Haemost 2008; 6: 104–110.
37. Wang L, et al. P2 receptor mRNA expression profiles in human lymphocytes, monocytes and CD34+ stem and progenitor cells. BMC Immunol 2004; 5: 16.
38. Colognato R, et al. Differential expression and regulation of protease-activated receptors in human peripheral monocytes and monocyte-derived antigen-presenting cells. Blood 2003; 102: 2645–2652.
39. Bolton SJ, et al. Expression of and functional responses to protease-activated receptors on human eosinophils. J Leukoc Biol 2003; 74: 60–68.
40. Jonnalagadda D, et al. Platelet secretion is kinetically heterogeneous in an agonist-responsive manner. Blood 2012; 120: 5209–5216.
41. Reichel CA, et al. Chemokine receptors Ccr1, Ccr2, and Ccr5 mediate neutrophil migration to postischaemic tissue. J Leukoc Biol 2006; 79: 114–122.
42. Drechsler M, et al. Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis in mice. Circulation 2010; 122: 1837–1845.
43. Grommes J, et al. CCR5 and FPR1 Mediate Neutrophil Recruitment in Endotox-in-Induced Lung Injury. J Innate Immun 2014; 6: 111–116.
44. Reininger AJ, et al. A 2-step mechanism of arterial thrombus formation induced by human atherosclerotic plaques. J Am Coll Cardiol 2010; 55: 1147–1158.